Tadalafil citrate emerged in the early 1990s as IC351 and was brought to market through a collaboration between ICOS and Eli Lilly. It functions by inhibiting PDE5, enhancing erectile response during sexual arousal. Unlike earlier treatments, its β-carboline structure provides a longer half-life and reduced off-target effects. Approved by the FDA in 2003, tadalafil citrate quickly became known for its “weekend effect,” maintaining efficacy for up to 36 hours and offering a more relaxed, flexible treatment experience for men with ED.
Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Cialis 50 by Stealth Labs, consult with your doctor or healthcare professional.
Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.
Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.
Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.